JN.1 Subvariant SARS CoV-2 rS Vaccine(Novavax)

The development agreement will see Fresenius Kabi’s cell therapy processing technologies integrated into Cellular Origins’ robotic platform. Credit: Kotin/Shutterstock. Fresenius Kabi and Cellular Origins have announced a partnership to advance the field of cell and gene therapy (CGT) by automating the manufacturing process. Fresenius Kabi’s cell therapy processing technologies will be integrated into Cellular Origins’ Constellation robotic platform. The partnership’s primary objective is to streamline the production of cell therapies at scale, maintaining the use of developers’ preferred tools for processing. This initiative automates the production of advanced therapies, aiming to enhance production efficiency and reduce the risk of human error-induced inconsistencies. The integration process will initially concentrate on Fresenius Kabi’s Cue cell processing system. This system is expected to be fully automated within Constellation, covering aspects from consumable transport to full process operation and data management. See Also: mRNA Covid-19 vaccines may boost cancer immunotherapy effectiveness UNICEF secures one million mpox vaccines for Africa Cellular Origins CEO Dr Edwin Stone stated: “Cellular Origins has developed Constellation to enable fully industrialised manufacture of cell and gene therapies. “Forming strong collaborations is essential to ensuring the industry can implement the transformative power of automation whilst using the tools that are best for the biology and, therefore, for patients. Fresenius Kabi is an industry-leading developer of automated technologies to support the production of cell therapies. “This is why we are excited to be working closely with their team to unlock the power of automation throughout the entire manufacturing process, with the goal of bringing life-saving therapies to patients, faster and more affordably.” The companies will begin their integration efforts with the Cue cell processing system, which is tailored for automated and precise small-volume cell processing. Following success with Cue, the partnership then plans to extend its focus to include Fresenius Kabi’s broader cell therapy technology portfolio, such as the Lovo cell processing system and other products currently under development. In October 2024, Fresenius Kabi won US Food and Drug Administration approval for Otulfi (ustekinumab-aauz), a Stelara biosimilar. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

Dive Brief:GSK says it owns seven patents that provide the foundation for Modernas messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement.At issue is the work of a team led by Christian Mandl, who was a top official in the vaccines unit at Novartis between 2008 and 2015. According to the lawsuit, Mandls team discovered new formulations and methods of preparing mRNA vaccines, overcoming hurdles that had long prevented development of successful shots using the technology.The team filed for patents on their work in 2010. GSK then acquired that intellectual property when it took over much of Novartis vaccines business in 2015. Now, GSK is saying Modernas COVID-19 vaccines infringe those patents and is seeking damages. A Moderna spokesperson said the company is aware of the suit and will defend itself against the claims.Dive Insight:Moderna, along with rivals Pfizer and BioNTech, achieved an astonishing public health success by developing an mRNA vaccine to fight the COVID-19 pandemic in less than a year. The companies also earned billions of dollars, sparking a series of legal battles over the patents involved.Moderna sparred with the U.S. government over intellectual property claims early in the pandemic. In February 2022, Arbutus Biopharma and Genevant Sciences sued Moderna over patents related to the delivery of mRNA shots. Weeks later, Alnylam Pharmaceuticals sued both Moderna and Pfizer, claiming that the companies violated an Alnylam patent on lipid nanoparticle technology.The legal battles didnt stop there. Another mRNA specialist, CureVac, sued BioNTech in July 2022. The following month, Moderna sued Pfizer and BioNTech, which then evened the score a year later by asking the U.S. government to dismiss some of Modernas patents.Earlier this year, GSK also sued Pfizer and BioNTech, alleging infringement on different patents stemming from the work of Mandls team and former Novartis researcher, Andrew Geall.In the latest lawsuit, filed in federal court in Delaware, GSK says Moderna could not have succeeded in the lightning-quick development of its COVID-19 vaccine without the work of Mandls team.Moderna has repeatedly touted the speed at which it produced its original Spikevax vaccine and was later able to modify it to address new viral strains, GSK said. But Moderna has consistently failed to acknowledge how it applied the Mandl teams revolutionary platform to do so.GSK is asking a jury to award unspecified damages and a licensing fee for its patents. Its also seeking to be reimbursed for attorney fees and costs incurred in the lawsuit. '